Key result
PET/CT demonstrated superior sensitivity compared to bone marrow biopsy for detecting bone marrow involvement in patients with diffuse large B-cell lymphoma (92.3% vs. 38.5%).
Why the study?
Does FDG PET/CT scanner improve the detection of bone marrow involvement and predict survival compared to bone marrow biopsy in patients with DLBCL?
Observational (n=54)
Blinded assessment
No
Does FDG PET/CT scanner improve the detection of bone marrow involvement and predict survival compared to bone marrow biopsy in patients with DLBCL?
Absolute Event Rate: 92.3% vs 38.5%
PET/CT shows superior sensitivity to bone marrow biopsy for detecting marrow involvement in DLBCL and provides independent prognostic value for survival.
May support PET/CT for marrow assessment in DLBCL; leaves open replacement of biopsy pending prospective validation.
Evaluation of bone marrow involvement (BMI) is paramount in diffuse large B-cell lymphoma (DLBCL) for prognostic and therapeutic reasons. PET/CT scanner (PET) is now a routine examination for the staging of DLBCL with prognostic and therapeutic implications. This study evaluates the role of PET for detecting marrow involvement compared to bone marrow biopsy (BMB). This monocentric study included 54 patients diagnosed with DLBCL between 2009 and 2013 and who had FDG PET/CT in a pre-treatment setting. A correlation analysis of the detection of BMI by PET and BMB was performed. A prognostic evaluation of BMI by BMB and/or PET/CT and correlation with an overall 2-year survival were analyzed. PET was more sensitive for the detection of BMI than BMB (92.3% vs. 38.5%). It can be considered a discriminatory Pre-BMB test with a negative predictive value of 97.6%. In addition, BMI by PET had a prognostic value with strong correlation with progression-free survival (PFS) (HR = 3.81; p = 0.013) and overall survival (OS) (HR = 4.12; p = 0.03) while the BMB had not. PET shows superior performance to the BMB for the detection of marrow involvement in DLBCL. It may be considered as the first line examination of bone marrow instead of the biopsy.
No takes yet. Share an insight, caveat, or question.
Karak et al. (2017) conducted an observational in Diffuse Large B-Cell Lymphoma (n=54). PET/CT scanner vs. Bone marrow biopsy was evaluated on Sensitivity for detection of bone marrow involvement. PET/CT demonstrated superior sensitivity compared to bone marrow biopsy for detecting bone marrow involvement in patients with diffuse large B-cell lymphoma (92.3% vs. 38.5%).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: